Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Gilead Sciences, Inc (NASDAQ: GILD) closed at $127.12 in the last session, up 1.48% from day before closing price of $125.27. In other words, the price has increased by $1.48 from its previous closing price. On the day, 7.59 million shares were traded. GILD stock price reached its highest trading level at $127.61 during the session, while it also had its lowest trading level at $124.7.
Ratios:
We take a closer look at GILD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.21. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.45. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 1.03.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $140. Daiwa Securities Upgraded its Neutral to Outperform on August 19, 2025, while the target price for the stock was maintained at $128.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 17 ’25 when Dickinson Andrew D sold 2,500 shares for $125.23 per share. The transaction valued at 313,075 led to the insider holds 154,555 shares of the business.
Mercier Johanna sold 28,000 shares of GILD for $3,524,173 on Nov 17 ’25. The Chief Commercial Officer now owns 107,193 shares after completing the transaction at $125.86 per share. On Nov 17 ’25, another insider, JOHANNA MERCIER, who serves as the Officer of the company, bought 28,000 shares for $125.86 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GILD now has a Market Capitalization of 157731373056 and an Enterprise Value of 174082195456. As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.69, and their Forward P/E ratio for the next fiscal year is 14.59. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.43 while its Price-to-Book (P/B) ratio in mrq is 7.33. Its current Enterprise Value per Revenue stands at 5.985 whereas that against EBITDA is 12.315.
Stock Price History:
The Beta on a monthly basis for GILD is 0.32, which has changed by 0.35558927 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, GILD has reached a high of $128.70, while it has fallen to a 52-week low of $88.57. The 50-Day Moving Average of the stock is 6.77%, while the 200-Day Moving Average is calculated to be 13.24%.
Shares Statistics:
According to the various share statistics, GILD traded on average about 7.23M shares per day over the past 3-months and 7881490 shares per day over the past 10 days. A total of 1.24B shares are outstanding, with a floating share count of 1.24B. Insiders hold about 0.21% of the company’s shares, while institutions hold 88.28% stake in the company. Shares short for GILD as of 1763078400 were 17007031 with a Short Ratio of 2.49, compared to 1760486400 on 15804496. Therefore, it implies a Short% of Shares Outstanding of 17007031 and a Short% of Float of 1.37.
Dividends & Splits
The forward annual dividend rate for GILD is 3.14, which was 3.14 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.025065858. The stock’s 5-year Average Dividend Yield is 3.85. . The current Payout Ratio is 805.23% for GILD, which recently paid a dividend on 2025-09-15 with an ex-dividend date of 2025-12-15. Stock splits for the company last occurred on 2013-01-28 when the company split stock in a 2:1 ratio.
Earnings Estimates
At present, 20.0 analysts are actively evaluating the performance of Gilead Sciences, Inc (GILD) in the stock market.The consensus estimate for the next quarter is $2.05, with high estimates of $2.19 and low estimates of $1.85.
Analysts are recommending an EPS of between $8.43 and $8.05 for the fiscal current year, implying an average EPS of $8.17. EPS for the following year is $8.72, with 28.0 analysts recommending between $9.5 and $6.38.
Revenue Estimates
According to 19 analysts, . The current quarter’s revenue is expected to be $7.65B. It ranges from a high estimate of $8.2B to a low estimate of $6.95B. As of . The current estimate, Gilead Sciences, Inc’s year-ago sales were $7.57BFor the next quarter, 19 analysts are estimating revenue of $7.04B. There is a high estimate of $7.25B for the next quarter, whereas the lowest estimate is $6.9B.
A total of 25 analysts have provided revenue estimates for GILD’s current fiscal year. The highest revenue estimate was $29.72B, while the lowest revenue estimate was $28.6B, resulting in an average revenue estimate of $29.21B. In the same quarter a year ago, actual revenue was $28.75BBased on 27 analysts’ estimates, the company’s revenue will be $30.08B in the next fiscal year. The high estimate is $31.25B and the low estimate is $28.72B.
